Arginase promotes endothelial dysfunction and hypertension in obese rats

Obesity

Volumn 23, Issue 2, 2015, Pages 383-390

  Johnson, Fruzsina K ^a   Peyton, Kelly J ^b   Liu, Xiao Ming ^b   Azam, Mohammed A ^b   Shebib, Ahmad R ^b   Johnson, Robert A ^a   Durante, William ^b  

^a LINCOLN MEMORIAL UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARGINASE; ARGINASE INHIBITOR; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; VASODILATATION; ZUCKER FATTY RAT; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; COMPLICATION; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; ZUCKER RAT;

ANIMALIA; RATTUS;

ANIMALS; ARGINASE; ARTERIOLES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HYPERTENSION; MALE; OBESITY; RATS; RATS, ZUCKER; REAL-TIME POLYMERASE CHAIN REACTION; RNA; VASODILATION;

EID: 84922699548     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20969     Document Type: Article

References (39)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM,. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Burke GL, Bertoni AG, Shea S, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 2008; 168: 928-935.
3. Lansberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment-a position paper of the Obesity Society and the American Society of Hypertension. Obesity 2013; 21: 8-24.
4. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment-a position paper of the Obesity Society and the American Society of Hypertension. Obesity 2013; 21: 8-24.
5. Stepp DW,. Impact of obesity and insulin resistance on vasomotor tone: nitric oxide and beyond. Clin Exp Pharmacol Physiol 2006; 33: 407-414.
6. Zucker LM,. Hereditary obesity in the rat associated with hyperlipidemia. Ann NY Acad Sci 1965; 131: 447-458.
7. Kasiske BL, O'Donnel MP, Keane WF,. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992; 19: 110-115.
8. Frisbee JC, Stepp DW,. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 2001; 281: H1304-H1311.
9. Johnson FK, Johnson RA, Durante W, Jackson KE, Stevenson BK, Peyton KJ,. Metabolic syndrome increases endogenous carbon monoxide production to promote endothelial dysfunction in obese Zucker rats. Am J Physiol Reg Integr Comp Physiol 2006; 290: R601-R608.
10. Durante W, Johnson FK, Johnson RA,. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007; 34: 906-911.
11. Morris SM Jr,. Arginine metabolism: boundaries of our knowledge. J Nutr 2007; 137: 1602S-1609S.
12. Durante W,. Role of arginase in vessel wall remodeling. Front Immunol 2013; 4: 111.
13. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294: 81-90.
14. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL,. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009; 53: 2061-2067.
15. Johnson FK, Johnson RA, Peyton KJ, Shebib AR, Durante W,. Arginase promotes skeletal muscle arteriolar endothelial dysfunction in diabetic rats. Front Immunol 2013; 4: 119.
16. Fulton D, Marris MB, Kemp BE, Venema RC, Marrero MB, Stepp DW,. Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90. Am J Physiol Heart Circ Physiol 2004; 287: H2384-2393.
17. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102: 95-102.
18. Giri H, Muthuramu I, Dhar M, Rathnakumar K, Ram U, Dixit M,. Protein tyrosine phosphatase SHP2 mediates chronic insulin-induced endothelial inflammation. Arterioscler Thromb Vasc Biol 2012; 32: 1943-1950.
19. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM,. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation 2001; 72: 1625-1631.
20. Ikemoto M, Tsunekawa S, Toda Y, Totani M,. Liver-type arginase is a highly sensitive marker for hepatocellular damage in rats. Clin Chem 2001; 47: 946-948.
21. Erdely A, Kepka-Lenhart D, Salmen-Muniz R, et al. Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 2010; 5: e15253.
22. Kim OY, Lee SM, Chung JH, Do HJ, Moon J, Shin MJ,. Arginase I and the very low-density lipoprotein receptor are associated with phenotypic biomarkers for obesity. Nutrition 2012; 28: 635-639.
23. Jung C, Figulla HR, Lichtenauer M, Franz M, Pernow J,. Increased levels of circulating arginase I in overweight compared to normal weight adolescents. Pediatr Diabetes 2014; 15: 51-56.
24. Ogino K, Takahashi N, Takigawa T, Obase Y, Wang D-H,. Association of serum arginase I with oxidative stress in a healthy population. Free Radic Res 2011; 42: 147-155.
25. Sailer M, Dahlhoff C, Giesbertz P, et al. Increased plasma citrulline in mice marks diet-induced obesity and may predict the development of the metabolic syndrome. PLoS One 2013; 8: e63950.
26. She P, Van Horne C, Reid T, Hutson SM, Cooney RN, Lynch CJ,. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab 2007; 293: E1552-E1563.
27. Wijekoon EP, Skinner C, Brosnan ME, Brosnan JT,. Amino acid metabolism in the Zucker diabetic fatty rat: effect of insulin resistance and type 2 diabetes. Can J Physiol Pharmacol 2004; 82: 506-514.
28. Caballero B, Finer N, Wurtman RJ,. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and dietary supplements. Metabolism 1988; 37: 672-676.
29. Newgard CB, An J, Bain JR, et al. A branched chain amino acid related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-326.
30. Felig P, Marliss E, Cahill GF,. Plasma amino acid levels and insulin secretion secretion in humans. N Engl J Med 1969; 281: 811-816.
31. Popov D, Costache G, Georgescu A, Enache M,. Beneficial effects of l -arginine supplementation in experimental-hyperglycemia in the hamster. Cell Tissue Res 2002; 308: 109-120.
32. El Bassossy H, El-Fawal R, Fahmy A,. Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production. Vascul Pharmacol 2012; 57: 194-200.
33. El-Basossy HM, El-Fawal R, Fahmy A, Watson ML,. Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol 2013; 169: 693-703.
34. Castejon AM, Hoffmann IS, Jimenez E, Cubeddu RJ, Baldonedo RM, Cubeddu LX,. Differential blood pressure effects of oral glucose and intravenous l -arginine in healthy lean normotensive and obese hypertensive subjects. J Hum Hypertens 2002; 16: S133-S136.
35. Marliss EB, Chevalier S, Gougeon R, et al. Elevations in plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006; 49: 351-359.
36. Wu G, Meininger CJ,. Arginine nutrition and cardiovascular function. J Nutr 2000; 130: 2626-2629.
37. Rhoo S, Gupta G, Benjo A, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008; 102: 923-932.
38. Fu WJ, Haynes TE, Kohli R, et al. Dietary l -arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr 2005; 135: 714-721.
39. Bogdanski P, Suliburska J, Grabanska K, et al. Effect of 3-month l -arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity. Eur Rev Med Pharmacol Sci 2012; 16: 816-823.